Weight Loss CAS 96829-58-2 Orlistat Powder for Treat Obesity

Product Details
Customization: Available
Application: Home
Disposable: Non-Disposable
Still deciding? Get samples of US$ 400/Gram
Request Sample
Diamond Member Since 2021

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Registered Capital
10000000 RMB
Plant Area
101~500 square meters
  • Weight Loss CAS 96829-58-2 Orlistat Powder for Treat Obesity
  • Weight Loss CAS 96829-58-2 Orlistat Powder for Treat Obesity
  • Weight Loss CAS 96829-58-2 Orlistat Powder for Treat Obesity
  • Weight Loss CAS 96829-58-2 Orlistat Powder for Treat Obesity
  • Weight Loss CAS 96829-58-2 Orlistat Powder for Treat Obesity
  • Weight Loss CAS 96829-58-2 Orlistat Powder for Treat Obesity
Find Similar Products

Basic Info.

Model NO.
HNB-0056
Gender
Unisex
Side Effect
No
Usage
For Oral Administration
Pharmaceutical Technology
Chemical Synthesis
Efficacy
Weight Loss & Slimming
Transport Package
Aluminium Foil Bag, Cardboard Drum
Trademark
HNB-Biotech
Origin
Shaanxi, China
Production Capacity
5000kg/Month

Product Description

Weight Loss CAS 96829-58-2 Orlistat powder for Treat Obesity

Weight Loss CAS 96829-58-2 Orlistat Powder for Treat Obesity
Product name Orlistat
Cas No. 96829-58-2
Molecular Formula C29H53NO5
Appearance White crystalline powder

Orlistat belongs to the lipase inhibitor class of weight loss drugs. It is a hydrating derivative of lipstatin, which can reduce the absorption of fat in food, thus leading to weight loss.This product has a strong and selective inhibitory effect on gastric lipase and pancreatic lipase, and has no effect on other digestive enzymes (amylase, trypsin, chymotrypsin) and phospholipase, and does not affect the absorption of carbohydrates, proteins and phospholipids.The drug was not absorbed by the gastrointestinal tract and the inhibition of lipase was reversible.
Orlistat mainly inactivates the enzyme in the gastrointestinal tract by covalently binding with the serine residues in the active sites of gastric lipase and pancreatic lipase, inhibiting the hydrolysis of triacylglycerol, reducing the intake of mono glycerol and free fatty acids, thus controlling body weight.The pharmacological activity of orlistat is dose-dependent, and the therapeutic dose of orlistat (120 mg/ d, tid, taken with meals) in combination with a slightly low-calorie balanced diet reduces dietary fat absorption by 30%.

Weight Loss CAS 96829-58-2 Orlistat Powder for Treat ObesityWeight Loss CAS 96829-58-2 Orlistat Powder for Treat ObesityWeight Loss CAS 96829-58-2 Orlistat Powder for Treat ObesityWeight Loss CAS 96829-58-2 Orlistat Powder for Treat ObesityWeight Loss CAS 96829-58-2 Orlistat Powder for Treat ObesityWeight Loss CAS 96829-58-2 Orlistat Powder for Treat ObesityWeight Loss CAS 96829-58-2 Orlistat Powder for Treat Obesity
 

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier